Sonoma pharmaceuticals reports recent publication from australia highlighting potential for microdox in managing urinary tract infections

Boulder, co / accesswire / april 4, 2024 / sonoma pharmaceuticals, inc. (nasdaq:snoa), a global healthcare leader developing and producing patented microcyn® technology based stabilized hypochlorous acid (hocl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions and podiatry, reported a recent publication in the journal neurourology and urodynamics highlighting the potential for microdox® in the management of urinary tract infections, or utis, in children with neurogenic or non‐neurogenic bladder dysfunction.[1] microdox is a super-oxidized solution based on sonoma's patented microcyn technology intended to treat and prevent infections in the urinary tract and bladder.
SNOA Ratings Summary
SNOA Quant Ranking